Exova Group PLC Appointment of Senior Independent Director (5887J)
18 Dicembre 2015 - 1:16PM
UK Regulatory
TIDMEXO
RNS Number : 5887J
Exova Group PLC
18 December 2015
Exova Group plc
(the "Company")
18 December 2015
Appointment of Senior Independent Director
On 28 August 2015, the Company announced that Allister
Langlands, currently Exova's Senior Independent Director, will
replace Fred Kindle as Non-Executive Chairman with effect from 1
January 2016.
The Company is pleased to announce that Bill Spencer will
replace Allister Langlands as Senior Independent Director with
effect from 1 January 2016. Bill became a Non-Executive Director of
the Company in advance of its IPO in April 2014 and he was a
Non-Executive Director of the previous parent company of the Exova
Group from July 2011.
Bill has extensive experience of the testing, inspection and
certification industry. He began working in the industry in 1992,
when he joined Inchcape Testing Services (part of Inchcape plc) as
a Financial Controller. He later became the Finance Director of the
Testing Services Division of Inchcape plc. In this role, he led the
buy-out when Intertek acquired the testing business from Inchcape
in 1996. He continued as the Chief Financial Officer of Intertek
upon its IPO in 2002. He was the Chief Financial Officer of
Intertek Group plc until 2010.
Bill is a Chartered Management Accountant and Corporate
Treasurer and has a BSc in Management Sciences from the University
of Manchester. He is a non-executive director and Audit Committee
Chairman of UK Mail Group plc and an independent non-executive
member of the Finance Committee of the Royal Institution of
Chartered Surveyors.
For further information please contact:
Neil MacLennan
General Counsel and Company Secretary
Exova Group plc
Telephone: +44 (0) 131 333 8053
About Exova
Exova is one of the world's leading laboratory-based testing
groups, trusted by organisations to test and advise on the safety,
quality and performance of their products and operations.
Headquartered in Edinburgh, UK, Exova operates 144 laboratories and
offices in 32 countries and employs around 4,500 people throughout
Europe, the Americas, the Middle East and Asia/Asia Pacific.
Exova's capabilities help to extend asset life, bring
predictability to applications, and shorten the time to market for
customers' products, processes and materials. With over 90 years'
experience, Exova specialises in testing across a number of key
sectors from health sciences to aerospace, transportation, oil and
gas, fire and construction.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAMMMMZZRZGKZM
(END) Dow Jones Newswires
December 18, 2015 07:16 ET (12:16 GMT)
Grafico Azioni Exova (LSE:EXO)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Exova (LSE:EXO)
Storico
Da Lug 2023 a Lug 2024
